Results 121 to 130 of about 23,034 (273)

SLC7A11: a new regulator in diabetic wound healing

open access: yesSignal Transduction and Targeted Therapy, 2022
Shunli Rui, Yu Ma, Wuquan Deng
openaire   +3 more sources

Essentiality of SLC7A11-mediated nonessential amino acids in MASLD

open access: yesScience Bulletin
Metabolic dysfunction-associated steatotic liver disease (MASLD) remains a rapidly growing global health burden. Here, we report that the nonessential amino acid (NEAA) transporter SLC7A11 plays a key role in MASLD. In patients with MASLD, we found high expression levels of SLC7A11 that were correlated directly with clinical grade.
Jie, Shen   +6 more
openaire   +2 more sources

SUMOylation regulates tumorigenesis and progression: Molecular mechanisms and therapeutic applications

open access: yesInterdisciplinary Medicine, EarlyView.
SUMOylation, a dynamic post‐translational modification, acts as a master regulator at the heart of tumor malignancy. Our work delineates how the SUMOylation cycle—mediated by E1/E2/E3 enzymes and reversed by SENPs—orchestrates multiple hallmarks of cancer. The central pathway converges on three critical pathological axes: 1.
Yimao Wu   +6 more
wiley   +1 more source

SLC7A11-HSPB1 axis: A novel mechanism for hepatocellular carcinoma progression and ferroptosis regulation

open access: yesBiomedical Journal
Background: SLC7A11, a plasma membrane protein, has been implicated as an oncogene in various cancers, including hepatocellular carcinoma (HCC). Its role in HCC pathogenesis, particularly in relation to ferroptosis, is not well understood.
Yan An   +4 more
doaj   +1 more source

Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis [PDF]

open access: yes, 2015
published_or_final_versio
Chen, J   +8 more
core  

AhR signaling modulates Ferroptosis by regulating SLC7A11 expression

open access: yesToxicology and Applied Pharmacology
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is pivotal in development, metabolic homeostasis, and immune responses. While recent research has highlighted AhR's significant role in modulating oxidative stress responses, its mechanistic relationship with ferroptosis-an iron-dependent, non-apoptotic cell death ...
Ziyue, Kou   +7 more
openaire   +2 more sources

Peri‐implant hypoxia as a potential barrier against ferroptotic mechanisms during peri‐implant diseases: A cross‐sectional study

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Hypoxia modulates inflammation and oxidative stress through hypoxia‐inducible factor‐1α (HIF‐1α). Ferroptosis, an iron‐dependent cell death process, is regulated by glutathione peroxidase‐4 (GPX4) and involves lipid peroxidation markers like malondialdehyde (MDA).
Büşra Yılmaz   +5 more
wiley   +1 more source

SLC7A11 is a potential therapeutic target and prognostic biomarker correlated with immune cell infiltration in cervical cancer

open access: yesDiscover Oncology
Background SLC7A11 is importantly in both ferroptosis and disulfidptosis which participated in human development and homeostasis. By utilizing bioinformatics and in vitro validation, we explored SLC7A11's role in cervical cancer.
Mutangala Muloye Guy   +7 more
doaj   +1 more source

Biological activities and bioactive constituents of Flammulina velutipes: An updated systematic review

open access: yesJournal of the Science of Food and Agriculture, EarlyView.
Abstract Flammulina velutipes (enokitake) is an edible mushroom recognized for both its nutritional and medicinal properties. It exhibits a broad spectrum of biological activities, including antioxidant, anti‐inflammatory, antitumor, immunomodulatory, and gut microbiota‐regulating effects.
Rıdvan Özgen   +2 more
wiley   +1 more source

USP54 Promotes Ferroptosis in Non‐Small Cell Lung Cancer by Mediating FOXA2 Deubiquitination and Enhancing ACSL4 Transcription

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer, with a 5‐year survival rate of less than 20% and a high risk of recurrence despite advances in treatment. This study aimed to identify new therapeutic targets to increase the effectiveness of NSCLC treatments.
Rui‐Shi Wei   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy